Peptide Decoding
New?New to peptides?Start here →
Decoding

AZD6234_Dosage, benefits & legal status

Corrected November 14, 2026: receptor selectivity and 1 earlier

Also known as lenbelintide, the drug name on AstraZeneca's three phase 3 SELENE trial records at ClinicalTrials.gov since September 2026 and a WHO recommended international nonproprietary name since March 2026.

Published October 4, 2026 · Updated November 14, 2026

An experimental weekly fullness-hormone shot from AstraZeneca, built to act like natural amylin.

Weight lossAmylin analogInvestigational
DoseOnce weekly in trials; milligram dose levels have not been publicly disclosed
FrequencyWeekly
RouteUnder the skin (subcutaneous)
StatusInvestigational
CycledNot cycled in the trials

See how this dose compares across the library →

01

What is AZD6234?

Plain language first. The technical label stays, but it never stands alone.

Overview

It copies the fullness hormone your pancreas makes, to reduce appetite. It is still experimental.

The technical version

AZD6234 is a long-acting amylin analog with a receptor profile matching native amylin (AMY3R/CTR relative potency 1.6 in human cells, 0.9 in rat).

What it's used for

An experimental weekly shot that copies a natural fullness hormone to reduce appetite.

02

How does AZD6234 work?

What it does in the body, and where.

AZD6234 is a long-acting amylin analog. AstraZeneca calls it a selective amylin receptor agonist; the WHO entry that names it lenbelintide calls it a dual amylin and calcitonin receptor agonist. The measured numbers explain why both labels are in use.

  1. 01
    It works through amylin receptors
    Fullness signaled through the brainstem rather than the gut-hormone route.
  2. 02
    How selective it is
    In AstraZeneca's cell assays, presented at EASD in September 2024, AZD6234's potency at the amylin-3 receptor relative to the calcitonin receptor was 1.6 in human cells and 0.9 in rat cells, a profile the authors describe as matching pramlintide and mimicking native amylin. A ratio that close to 1 means it activates both receptors at close to equal potency. "Selective" in AstraZeneca's usage means it does not favor the calcitonin receptor the way the DACRA compounds do. WHO's naming entry from July 2025 classes it as a dual amylin/calcitonin receptor agonist, and the same numbers fit that label. Of the two, the bare word "selective" is the weaker description, because a ratio near 1 is not what most readers picture when they read it. An earlier version of this page gave the ratio as roughly 14; that was a misreading of the abstract's experiment count.
  3. 03
    Three phase 3 trials were recruiting as of November 2026. No approval anywhere.
Anatomical illustration highlighting metabolic organs
WHAT THIS COMPOUND ACTS ON:
amylinFullness from the pancreas
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Weight loss, positioned by AstraZeneca as a selective amylin-receptor optionInvestigational

The published record

Research index

2

Papers about AZD6234 · this compound only

Searched: AZD6234, lenbelintide.

18 papers tagged human · 0 not reviews or lab · 0 clinical trial publications

16 registered trials · none with posted results

Furthest stage reached: Phase 3, under way

Compare this against the whole library →

In animals2
In the lab0
Reviews2
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

AZD6234 vial rendering
Compound field notes

At a glance

Four things to know about AZD6234

01

Evidence

Investigational

02

Category

Weight loss and metabolic

03

Common vial

Varies

04

Half-life

About 4 days

04

How much, and do you cycle it?

The range, and whether you take breaks.

Once weekly in trials; milligram dose levels have not been publicly disclosed, weekly. Not cycled in the trials Trial dose

Given continuously for the whole study period, with the dose stepped up at the start, which is a ramp rather than a cycle.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

About 4 daysTrial protocol

Reported in a peer-reviewed review rather than in a primary pharmacokinetic paper: the review describes dose-proportional pharmacokinetics in the phase 1 single ascending dose study and a terminal half-life of approximately 4 days, which is what supports once-weekly dosing. The review was read in a reproduction of its PDF, because the publisher's own copy is not reachable from here. AstraZeneca has published no pharmacokinetic paper of its own, and the trial's own results are not posted.

Source: Alhazmi and le Roux, Amylin analogs: the next major class of weight loss therapy, Diabetes, Obesity and Metabolism 2026, reporting the phase 1 single ascending dose study (NCT05511025)

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Enter the amount printed on your label.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: The phase 2b trial lists three active dose groups and once-weekly injections, but does not disclose their milligram amounts. An earlier phase 1 study (NCT05511025) tested single subcutaneous doses of 0.3, 0.9, 1.5, 2.7, 3.0, and 4.2 mg. Those are study doses, not a dosing schedule, and no community convention has formed around this compound yet.Trial schedule

Choose your mix

mL water—units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units
07

How do you store it?

Before mixing, and after.

Nothing to store: it is not sold anywhere.

AZD6234 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 16% charged residues, 41% hydrophobic. Acid may help.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • Pregnancy or breastfeeding
  • Any prescription medicine you take regularly, without checking for interactions first
  • Anyone who wants established safety data, because none exists for this compound in humans

Stop and get help

These are emergencies. Seek care.
  • Spreading hives, swelling of the face or throat, or trouble breathing, which can happen with any injection and is a medical emergency
  • Redness, heat, or pus at the injection site, which can signal infection
  • Any severe or unexpected symptom
  • Anything unusual, since there is no known safety profile to compare it against

Common effects

Expected, and usually mild.
  • Stomach side effects.
  • Trial-only.
  • Redness, soreness, or a small bump at the injection site
  • Beyond the above, unknown. There is no reliable human data on what this compound commonly causes

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is AZD6234 approved?

And where the numbers on this page come from.

No. AZD6234 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

What has happened recently

Still in trials. Three phase 3 trials (SELENE 1, 2 and 3) were recruiting as of November 2026, under the name lenbelintide. It is not approved anywhere and long-term safety is unknown.

Guides for this compound

Sources

Beyond these, 18 records are indexed for this compound. Browse the records